Ipafricept

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ipafricept
Accession Number
DB15045
Type
Biotech
Groups
Investigational
Description

Ipafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).

Synonyms
  • OMP-54F28
Categories
UNII
2N71QUE3NL
CAS number
1391727-24-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ipafricept.
AbituzumabThe risk or severity of adverse effects can be increased when Abituzumab is combined with Ipafricept.
AbrilumabThe risk or severity of adverse effects can be increased when Ipafricept is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ipafricept.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Ipafricept.
AducanumabThe risk or severity of adverse effects can be increased when Aducanumab is combined with Ipafricept.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Ipafricept.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ipafricept.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ipafricept.
AmatuximabThe risk or severity of adverse effects can be increased when Amatuximab is combined with Ipafricept.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentTumors, Solid1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:44 / Updated on May 21, 2019 12:34